ArticleNeuropsychiatric disease and treatment2025
Serum Lipidome Change in Japanese Patients with Major Depressive Disorder: A Real-World Exploratory Study.
Article in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The LPC-ATX-LPA-LPAR Axis in Major Depressive Disorder: From PC/LPC Metabolism to Receptor-Active Lipid Signaling.International journal of molecular sciences · 2026Review
- Dynamic interactions between gut microbiome and host lipidome in antenatal depression: a large longitudinal study.Molecular psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Major depressive disorder (MDD) is a highly prevalent psychiatric condition with complex and heterogeneous biological underpinnings. Lipid dysregulation has emerged as a potential contributor to MDD pathophysiology. However, comprehensive lipidomic profiling studies in Japanese individuals remain limited. This study aimed to investigate serum lipidomic alterations in Japanese patients with MDD and explore the potential associations with depression severity. Patients and Methods: We conducted a real-world observational study including 30 Japanese patients with MDD and 30 healthy controls. Depression severity was assessed using the Montgomery-Asberg Depression Rating Scale. Lipidomic analysis identified 344 lipid peaks from serum samples. Multivariate and univariate statistical analyses were employed to identify differentially expressed lipids and their correlations with clinical symptoms. Results: Thirty lipids were found to differ significantly between groups, with 7 elevated and 23 reduced in the MDD cohort. Pathway enrichment analysis highlighted disruptions in lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), N-acylethanolamines, and fatty acylcarnitines. Notably, levels of LPC (20:3), platelet-activating factor (20:5), and platelet-activating factor (18:3) were negatively correlated with depression severity, suggesting a potential link to mood regulation. Conclusion: The pronounced enrichment changes observed in LPC and LPE-lipid species involved in membrane remodeling and cellular signal transduction-are consistent with previous findings. However, the observed negative correlations with psychiatric symptom severity were contrary to prior expectations. These results underscore the importance of interpreting lipidomic data in the context of specific population characteristics, methodological frameworks, and clinical settings. They suggest potentially meaningful metabolic alterations associated with MDD and provide a foundation for future longitudinal and mechanistic investigations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.